[Comment] Is Partial Complement Blockade Enough in Myasthenia Gravis?

Why It Matters

Understanding optimal therapy selection and safety management will directly affect outcomes for thousands of refractory myasthenia gravis patients and shape the commercial trajectory of high‑cost biologics.

Key Takeaways

• C5 inhibitors (eculizumab, ravulizumab, zilucoplan) reduce complement‑mediated damage.
• FcRn antagonists (efgartigimod, rozanolixizumab, nipocalimab) lower pathogenic IgG levels.
• Inebilizumab depletes CD19 B cells, offering a distinct mechanism.
• Long‑term safety hinges on infection risk management, especially meningococcal.
• Biomarker‑driven patient selection remains the biggest unmet need.

Pulse Analysis

The therapeutic landscape for generalized myasthenia gravis (gMG) has been transformed by a wave of molecular agents that target distinct immunologic pathways. Complement C5 inhibitors such as eculizumab, ravulizumab, and the subcutaneous peptide zilucoplan block terminal complement activation, directly preventing neuromuscular junction damage. Parallel advances in FcRn antagonism—efgartigimod, rozanolixizumab, and nipocalimab—accelerate the catabolism of pathogenic IgG, while inebilizumab’s anti‑CD19 activity depletes B‑cell precursors, offering a third mechanism of disease control. These approvals, spanning 2017 to 2025, have expanded options for patients unresponsive to conventional immunosuppression.

Phase 3 trials consistently report rapid, clinically meaningful improvements in MG‑ADL and QMG scores, with response rates ranging from 40% to 70% depending on the agent and patient subgroup. Safety profiles are generally favorable, yet the risk of serious infections—particularly meningococcal disease with complement blockade—remains a pivotal concern. Moreover, the durability of response varies; some patients sustain benefit after dose tapering, while others require continuous high‑intensity dosing. The field lacks robust biomarkers to predict which individuals will derive maximal benefit from a given pathway, complicating treatment sequencing and cost‑effectiveness analyses.

Looking ahead, the industry is investing in precision‑medicine approaches that combine pharmacodynamic monitoring with genetic and serologic markers to refine patient selection. Combination regimens that pair complement inhibition with FcRn antagonists are under early investigation, aiming to achieve deeper, more durable remission while potentially lowering individual drug exposure. For pharmaceutical companies, the expanding gMG market—projected to exceed $5 billion globally—offers substantial revenue opportunities, but success will hinge on demonstrating differentiated efficacy, safety, and real‑world value. Clinicians, insurers, and patients alike will benefit from clearer guidance on optimal therapy pathways, ultimately translating scientific advances into improved quality of life.